Search
Filters
Clear All
  • 1
  • 14

Phase

  • 2
  • 3
  • 2
  • 6
  • 15
  • 2

Found 15 nabil-adra-md trials

A listing of nabil-adra-md medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Collection of Specimens and Clinical Data to Create a Biorepository for the Genitourinary Oncology Program

N
Nabil Adra, MD
18-100 years
All genders
The purpose of this study is to collect a variety of blood and cancer tissue specimens from patients with advanced kidney, bladder or prostate cancer.
Learn More

Pembrolizumab in MIBC

N
Nabil Adra, MD
18-100 years
All genders
Phase 2
Interventional
Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completingwo cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis with a standard acquisition protocol (as outlined in the protocol) as well as CT chest. A CThe abdomen and pelvis may be performed …
Learn More

Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT

N
Nabil Adra, MD
18-100 years
All genders
Phase 2
Interventional
This is an open label randomized phase II trial of maintenance oral etoposide vs. observationwith relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood(PBSCT).
Learn More

Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder (ADAPT)

N
Nabil Adra, MD
18-100 years
All genders
The main purpose of this phase 1 trial is to show that durvalumab is safe when given alone, in combination with BCG treatments, and in combination with radiation therapy. The overall goal of this trial is to see if the risk of your cancer coming back can be decreased with …
Learn More

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

N
Nabil Adra, MD
18-100 years
All genders
Phase 3
Interventional
This is a study of perioperative pembrolizumab or enfortumab vedotin in combination withbrolizumab in participants who are cisplatin-ineligible or decline cisplatin withuscle-invasive bladder cancer (MIBC). The primary hypothesis is that perioperative pembrolizumab plus radical cystectomy (RC) plusvic lymph node dissection (PLND) and perioperative enfortumab vedotin in combination withbrolizumab plus RC+PLND …
Learn More

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

N
Nabil Adra, MD
18-100 years
Male
Phase 1
Interventional
Evaluate the safety and tolerability of AMG 509 in adult participants and determine theum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Learn More

ARX517 in Subjects With Advanced Solid Tumor (ARX517)

N
Nabil Adra, MD
18-100 years
All genders
Phase 1
Interventional
A Phase 1, Multicenter, Open-label, Dose-escalation, and Dose expansion Study to Evaluate they, Pharmacokinetics, and Anti-tumor Activity of ARX517 in Subjects with Advanced Solid Tumor with known PSMA Who Failed Prior Standard Therapies
Learn More

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

N
Nabil Adra, MD
18-100 years
All genders
Phase 3
Interventional
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumabwed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed byvolumab with cabozantinib in patients with untreated renal cell carcinoma that has spreadher parts of the body. The addition of cabozantinib to the usual treatment may make …
Learn More

A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

N
Nabil Adra, MD
All genders
Phase 2
Interventional
The purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib forwith incurable, refractory germ cell tumors. Patients will be treated until evidencedisease progression, non-compliance with study protocol, unacceptable major toxicity, atubject's own request for withdrawal, or if the study closes for any reason.
Learn More

A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

N
Nabil Adra, MD
18-100 years
All genders
The purpose of this study is to compare any good and bad effects of using Atezolizumab along with the usual chemotherapy after progression with PD-1 or PD-L1 Inhibitor for individuals with urothelial carcinoma (cancer of the urinary tract).
Learn More
1 - 10 of 15